Healthcare provider profile · identity verified

Grant Wang, MD

Family Practice · BERKELEY, CA · NPI 1699755934

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	565	154
Amlodipine Besylate	Amlodipine Besylate	293	82
Lisinopril	Lisinopril	290	80
Hydrochlorothiazide	Hydrochlorothiazide	284	76
Losartan Potassium	Losartan Potassium	225	59
Metoprolol Succinate	Metoprolol Succinate	149	39
Levothyroxine Sodium	Levothyroxine Sodium	148	38
Simvastatin	Simvastatin	145	37
Tamsulosin Hcl	Tamsulosin Hcl	137	43
Trazodone Hcl	Trazodone Hcl	108	30
Fluoxetine Hcl	Fluoxetine Hcl	107	27
Pantoprazole Sodium	Pantoprazole Sodium	83	24
Gabapentin	Gabapentin	81	33
Omeprazole	Omeprazole	81	28
Metformin Hcl	Metformin Hcl	74	21
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	68	13
Pravastatin Sodium	Pravastatin Sodium	68	19
Eliquis	Apixaban	66	18
Rosuvastatin Calcium	Rosuvastatin Calcium	53	20
Fluticasone Propionate	Fluticasone Propionate	49	19
Zolpidem Tartrate	Zolpidem Tartrate	49	28
Potassium Chloride	Potassium Chloride	42	14
Finasteride	Finasteride	41	11
Albuterol Sulfate Hfa	Albuterol Sulfate	40	16
Escitalopram Oxalate	Escitalopram Oxalate	40	12
Xarelto	Rivaroxaban	40	suppressed
Citalopram Hbr	Citalopram Hydrobromide	39	suppressed
Allopurinol	Allopurinol	38	11
Famotidine	Famotidine	37	12
Celecoxib	Celecoxib	35	11
Donepezil Hcl	Donepezil Hcl	34	suppressed
Glimepiride	Glimepiride	34	suppressed
Valacyclovir	Valacyclovir Hcl	34	14
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	33	suppressed
Clopidogrel	Clopidogrel Bisulfate	32	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	32	suppressed
Estradiol	Estradiol	30	suppressed
Ketoconazole	Ketoconazole	30	suppressed
Metformin Hcl Er	Metformin Hcl	30	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	21
Atenolol	Atenolol	26	suppressed
Lorazepam	Lorazepam	26	11
Mirtazapine	Mirtazapine	25	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Valsartan	Valsartan	25	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	23	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Furosemide	Furosemide	21	suppressed
Ipratropium Bromide	Ipratropium Bromide	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Klor-Con 10	Potassium Chloride	19	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	19	19
Baclofen	Baclofen	18	suppressed
Carvedilol	Carvedilol	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Sertraline Hcl	Sertraline Hcl	18	suppressed
Alendronate Sodium	Alendronate Sodium	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Ozempic	Semaglutide	17	suppressed
Azithromycin	Azithromycin	16	16
Sildenafil Citrate	Sildenafil Citrate	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	15	suppressed
Lovastatin	Lovastatin	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Propranolol Hcl Er	Propranolol Hcl	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Diazepam	Diazepam	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Temazepam	Temazepam	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Colchicine	Colchicine	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Minoxidil	Minoxidil	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Prednisone	Prednisone	12	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error